What is the interaction between Cellcept (Mycophenolate Mofetil) and Augmentin (Amoxicillin-Clavulanate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2025 • View editorial policy

From the FDA Drug Label

Drugs that Interfere with Enterohepatic Recirculation Clinical Impact Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology (12. 3)] , which may reduce mycophenolate mofetil efficacy. Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil. Examples Trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials

The interaction between Cellcept (Mycophenolate Mofetil) and Augmentin (Amoxicillin-Clavulanate) is that concomitant use may decrease MPA systemic exposure, which may reduce mycophenolate mofetil efficacy, as Augmentin is a penicillin class of antimicrobial that can alter gastrointestinal flora and interfere with enterohepatic recirculation.

  • Key Points: + Concomitant use may decrease MPA systemic exposure + Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions + Augmentin is a penicillin class of antimicrobial that can interfere with enterohepatic recirculation 1

From the Research

Interaction between Cellcept (Mycophenolate Mofetil) and Augmentin (Amoxicillin-Clavulanate)

There are no research papers provided to directly assist in answering the question about the interaction between Cellcept (Mycophenolate Mofetil) and Augmentin (Amoxicillin-Clavulanate).

Available Information on Cellcept

  • Cellcept (Mycophenolate Mofetil) is an immunosuppressive drug that inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the purine synthesis pathway of lymphocytes 2.
  • It has a selective lymphocyte suppression effect, leading to a reduction in the incidence of rejection in renal allograft patients 2.
  • The drug has been shown to be effective in preventing allograft rejection and has a well-established efficacy in renal transplantation 3, 4, 5, 6.
  • Common side effects of Cellcept include hematologic and infectious adverse reactions 4, as well as gastrointestinal and hematopoietic system effects 2.

Lack of Information on Interaction with Augmentin

  • There is no information provided in the studies about the interaction between Cellcept (Mycophenolate Mofetil) and Augmentin (Amoxicillin-Clavulanate).
  • The studies primarily focus on the efficacy and safety of Cellcept in renal transplant patients, as well as its mechanisms of action and comparison with generic formulations 3, 4, 5, 2, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.